BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19502179)

  • 1. Bortezomib in treatment of extramedullary plasmacytoma of the pancreas.
    Wei JY; Tong HY; Zhu WF; Liu H; Zhang FJ; Yu WJ; Jin J
    Hepatobiliary Pancreat Dis Int; 2009 Jun; 8(3):329-31. PubMed ID: 19502179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of extramedullary gastric plasmacytoma with the combination of bortezomib and dexamethasone: first reported case.
    Katodritou E; Kartsios C; Gastari V; Verrou E; Mihou D; Banti A; Lazaraki G; Lazaridou A; Kaloutsi V; Zervas K
    Leuk Res; 2008 Feb; 32(2):339-41. PubMed ID: 17560647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First report of a medullar cord compression secondary to osseous plasmacytoma successfully treated with bortezomib and dexamethasone.
    Español I; Martínez A; López MD; Iturbe T; Tejedor A; García MC; Cavero S; Funes C; Ibáñez J
    Leuk Res; 2010 Apr; 34(4):e97-9. PubMed ID: 19836836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effective combination therapy of bortezomib and dexamethasone for two patients with refractory multiple myeloma].
    Ikeda H; Hayashi T; Nojima M; Yasui H; Ikeda Y; Ishida T; Adachi M; Imai K
    Rinsho Ketsueki; 2005 Apr; 46(4):269-73. PubMed ID: 16444959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib in relapsed multiple myeloma complicated by extramedullary plasmacytomas.
    Hughes M; Micallef-Eynaud P
    Clin Lab Haematol; 2006 Aug; 28(4):267-9. PubMed ID: 16898968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia.
    Kim SJ; Kim J; Cho Y; Seo BK; Kim BS
    Jpn J Clin Oncol; 2007 May; 37(5):382-4. PubMed ID: 17538191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Very good partial response and long time to progression by short-term bortezomib plus dexamethasone therapy for a patient with relapsed and refractory multiple myeloma-a case report].
    Fukushima T; Iwao H; Nakajima A; Miki M; Sakai T; Sawaki T; Tanaka M; Masaki Y; Hirose Y; Umehara H
    Gan To Kagaku Ryoho; 2009 Aug; 36(8):1387-9. PubMed ID: 19692786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of an extramedullary plasmacytoma despite disappearing M protein in multiple myeloma by bortezomib treatment].
    Koiso H; Tahara K; Osaki Y; Mawatari M; Sekigami T; Yokohama A; Saitoh T; Uchiumi H; Handa H; Tsukamoto N; Karasawa M; Nojima Y; Murakami H
    Rinsho Ketsueki; 2009 Feb; 50(2):78-82. PubMed ID: 19265298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
    Barlogie B; Anaissie E; van Rhee F; Haessler J; Hollmig K; Pineda-Roman M; Cottler-Fox M; Mohiuddin A; Alsayed Y; Tricot G; Bolejack V; Zangari M; Epstein J; Petty N; Steward D; Jenkins B; Gurley J; Sullivan E; Crowley J; Shaughnessy JD
    Br J Haematol; 2007 Jul; 138(2):176-85. PubMed ID: 17593024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome.
    Chim CS
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):181-2. PubMed ID: 17846773
    [No Abstract]   [Full Text] [Related]  

  • 12. Retro-peritoneal plasmacytoma: a case report and review of literature.
    Sharma LM; Biswas G; Rai SS; Nair R; Gupta S; Parikh PM
    Indian J Cancer; 2004; 41(3):133-4. PubMed ID: 15472413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib.
    Sood R; Carloss H; Kerr R; Lopez J; Lee M; Druck M; Walters IB; Noga SJ
    Am J Hematol; 2009 Oct; 84(10):657-60. PubMed ID: 19731393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
    Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of bortezomib at different doses in combination with dexamethasone in treatment of relapsed or refractory multiple myeloma: a comparative study].
    Bao L; Lu XJ; Zhang XH; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(26):1829-31. PubMed ID: 19040018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Side effects and good effects from new chemotherapeutic agents. Case 3. Bortezomib in primary refractory plasmacytoma.
    Chim CS; Ooi GC; Loong F; Au AW; Lie AK
    J Clin Oncol; 2005 Apr; 23(10):2426-8. PubMed ID: 15800336
    [No Abstract]   [Full Text] [Related]  

  • 18. Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?
    Katodritou E; Verrou E; Gastari V; Hadjiaggelidou C; Terpos E; Zervas K
    Leuk Res; 2008 Jul; 32(7):1153-6. PubMed ID: 18083228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia.
    Vela-Ojeda J; García-Ruiz Esparza MA; Rosas-Cabral A; Padilla-González Y; García-Chávez J; Tripp-Villanueva F; Sánchez-Cortés E; Ayala-Sánchez M; García-León LD; Montiel-Cervantes L; Rubio-Borja ME
    Ann Hematol; 2002 Jul; 81(7):362-7. PubMed ID: 12185504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib in multiple myeloma: treatment and retreatment. A single center experience.
    Warzocha K; Kraj M; Pogłód R; Kwaśniak B
    Acta Pol Pharm; 2008; 65(6):753-6. PubMed ID: 19172860
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.